Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial

Elevated circulating lipoprotein(a) levels are associated with an increased risk of cardiovascular events. We reported that early initiation of evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in addition to a statin substantially reduced the lipoprotein(a) levels in patients w...

Full description

Bibliographic Details
Main Authors:	Tomoaki Okada, Toru Miyoshi, Masayuki Doi, Kazumasa Nosaka, Ryu Tsushima, Satoko Ugawa, Wataru Takagi, Masahiro Sogo, Masahiko Takahashi, Hiroshi Ito
Format:	Article
Language:	English
Published:	MDPI AG 2022-05-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	evolocumab pitavastatin lipoprotein(a) percutaneous coronary intervention hypolipidemic agents myocardial infarction
Online Access:	https://www.mdpi.com/2308-3425/9/5/153

Similar Items

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
by: Martha L. Daviglus, et al.
Published: (2021-01-01)

RESULTS OF THE CLINICAL TRIAL FOURIER. NEW OPPORTUNITIES FOR TREATMENT OF VERY HIGH CARDIOVASCULAR RISK PATIENTS
by: Advisory Board
Published: (2017-06-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins
by: Chaoxuan Wang, et al.
Published: (2024-03-01)

Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease
by: Seung Woo Choi, et al.
Published: (2022-03-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Molecular characterization of the first avian LDL receptor
by: Susanna Hummel, et al.
Published: (2003-09-01)

Sex X Time Interactions in Lp(a) and LDL-C Response to Evolocumab
by: Federica Fogacci, et al.
Published: (2023-12-01)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
by: Henry CA, et al.
Published: (2016-04-01)

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study
by: Meng-Meng Yu, et al.
Published: (2023-05-01)

Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia
by: Kosmas CE, et al.
Published: (2018-10-01)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
by: Peter P. Toth, et al.
Published: (2017-10-01)

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
by: Heidi T. May, et al.
Published: (2019-03-01)

Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON
by: Alberto J. Lorenzatti, et al.
Published: (2021-04-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

EXPERIENCE WITH THE USE OF EVOLOCUMAB THERAPY IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA (IN KARELIA REPUBLIC)
by: V. A. Korneva, et al.
Published: (2020-06-01)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017-07-01)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01)

Real-World Application of Evolocumab Among Patients with Hyperlipidemia in Korea: A Multicenter Prospective Study
by: Min Chul Kim, et al.
Published: (2024-10-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty
by: Federica Fogacci, et al.
Published: (2021-08-01)

Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”
by: Azza Ramadan, et al.
Published: (2022-01-01)

Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency
by: Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
Published: (2023-10-01)

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
by: Maria K. Svensson, et al.
Published: (2024-01-01)

Extreme lipoprotein(a) in clinical practice: A cross sectional study
by: Barak Zafrir, et al.
Published: (2023-03-01)

Current therapies for lowering lipoprotein (a)
by: Julian C. van Capelleveen, et al.
Published: (2016-09-01)

Evolocumab-induced delayed skin hypersensitivity reaction in a patient with familial hypercholesterolaemia
by: Grzegorz Porebski, et al.
Published: (2024-02-01)

Evolocumab y sus posibles beneficios para una población en riesgo
by: Jimena Araya Vargas, et al.
Published: (2016-11-01)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
by: Borislav Borissov, et al.
Published: (2017-01-01)

Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling
by: Xuejie Han, et al.
Published: (2024-07-01)

Lotus root‐like appearance in the left anterior descending artery treated with a drug‐coated balloon angioplasty
by: Wataru Takagi, et al.
Published: (2022-07-01)

Evolocumab safety and efficacy in hypercholesterolemia patients with or without diabetes: a retrospective real-world analysis
by: Sultan Ibrahim Alraddadi, et al.
Published: (2025-01-01)

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
by: Fabrizio Calapai, et al.
Published: (2024-03-01)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
by: Zhenxian Li, et al.
Published: (2023-05-01)

Safety and Effectiveness of Low‐Density Lipoprotein Cholesterol–Lowering Therapy With Evolocumab for Familial Hypercholesterolemia/Hypercholesterolemia in Japan: A Real‐World, Postmarketing, Single‐Arm Study
by: Koutaro Yokote, et al.
Published: (2024-11-01)

Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis
by: Guoguang Xiao, et al.
Published: (2024-10-01)

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
by: Andreja Rehberger Likozar, et al.
Published: (2022-12-01)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
by: Frederick Berro Rivera, MD, et al.
Published: (2025-02-01)

Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention
by: Amalia Despoina Koutsogianni, et al.
Published: (2022-11-01)